AML | CHOP Research Institute


This study enrolls patients that have been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or mixed phenotype acute leukemia (MPAL) that has either come back (‘relapsed’) or does not respond to therapy (‘refractory’).

This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R).

Published on
Sep 8, 2023
Sarah K. Tasian, MD, received a $1 million grant to further her research into a novel immunotherapy for high-risk pediatric leukemias.
Published on
Jul 7, 2023
See highlights from the Third Annual Lymphatic Disorder Conference and Cellicon Valley ’23, and more in this week’s research news roundup.
Published on
Jun 22, 2023
Wei Tong, PhD, and colleagues found a protein interaction that appears to be a driver of hematologic malignancies.
Published on
May 19, 2021
CHOP Researchers find the novel mechanistic link by which MNI causes acute myeloid leukemia.

Shifting the paradigm to treat the toughest pediatric cancers with new cell therapies that reprogram a patient's own immune system to kill cancer cells.

Published on
Jun 10, 2020
Researchers at CHOP found that dexrazoxane lowers risk for cardiotoxicity associated with chemotherapy in pediatric AML
Published on
May 8, 2020
PolicyLab model updates reveal weather is having a greater impact on the spread of COVID-19 than previously indicated. This and more In the News.
Published on
Apr 16, 2020
Cancer researchers will use a proof-of-concept award to develop a novel immunotherapy for acute myeloid leukemia.